Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer

17 May 2024

Abstract excerpt

Mechanisms underlying primary and acquired resistance to MET tyrosine kinase inhibitors (TKIs) in managing non-small cell lung cancer remain unclear. In this study, we investigated the possible mechanisms acquired for crizotinib in MET-amplified lung carcinoma cell lines. Two MET-amplified lung cancer cell lines, EBC-1 and H1993, were established for acquired resistance to MET-TKI crizotinib and were functionally...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38758826
DOI: 10.1371/journal.pone.0300644

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancerPMID 38758826Read ↗

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung CancersSemantic proximity Read ↗

Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.Semantic proximity Read ↗

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.Semantic proximity Read ↗

Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cellsSemantic proximity Read ↗

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Semantic proximity Read ↗

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapySemantic proximity Read ↗

Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy.Semantic proximity Read ↗

Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.Semantic proximity Read ↗

Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical DataSemantic proximity Read ↗

RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Semantic proximity Read ↗

[Research Progress of Acquired Resistance Mediated by MET Amplification in Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.